Transgene - Transgene 2019 Annual Results

Speakers: Philippe Archinard, Chairman and CEO Jean-Philippe Del, VP Finance

Topics

• 2019 Financial results

• Creating individualized immunotherapies based on our molecular virology expertise

• Our next generation multifunctional oncolytics virus (OV) platform

• Presentation

• Promising Phase 1b Results with TG4001, in combination with avelumab

• Q&A